Angew Chem Int Ed Engl. 2011 Jun 30. doi: 10.1002/anie.201006565. [Epub ahead of print]
Malakoutikhah M, Teixidó M, Giralt E.
Institute for Research in Biomedicine (IRB Barcelona), Barcelona (Spain)
Keywords: shuttle-mediated drug delivery, blood-brain barrier (BBB), central nervous system, vector-mediated approach, ability to cross the BBB.
Tuesday, September 13, 2011
Sunday, September 11, 2011
Mesenchymal stem cells: from experiment to clinic
Fibrogenesis & Tissue Repair 2011, 4:20 doi:10.1186/1755-1536-4-20
William R Otto1 and Nicholas A Wright2
1 Histopathology Laboratory, Cancer Research UK, London Research Institute, London, UK. 2 Blizard Institute, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK.
"Good review, defines the current state of research and use of Mesenchymal stem cells"
William R Otto1 and Nicholas A Wright2
1 Histopathology Laboratory, Cancer Research UK, London Research Institute, London, UK. 2 Blizard Institute, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK.
"Good review, defines the current state of research and use of Mesenchymal stem cells"
Importance of Iron Chelation in Free Radical-Induced Oxidative Stress and Human Disease.
Curr Pharm Des. 2011 Sep 9,
Jomova K, Valko M.
Faculty of Chemical and Food Technology, Slovak Technical University, Bratislava, Slovakia.
Keywords: Iron, redox active metal, hemochromatosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedreich's ataxia, neurological disorders, cancer, Fanconi anemia, stroke, ageing, Fenton reaction, reactive oxygen species (ROS), iron-designed chelators.
Jomova K, Valko M.
Faculty of Chemical and Food Technology, Slovak Technical University, Bratislava, Slovakia.
Keywords: Iron, redox active metal, hemochromatosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedreich's ataxia, neurological disorders, cancer, Fanconi anemia, stroke, ageing, Fenton reaction, reactive oxygen species (ROS), iron-designed chelators.
Saturday, September 3, 2011
A listing of clinical trials currently looking for volunteers to enroll in Friedreich's Ataxia studies.
Austria, Innsbruck :
Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)
Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)
Roles of Porphyrin and Iron Metabolisms in the δ-Aminolevulinic Acid (ALA)-induced Accumulation of Protoporphyrin and Photodamage of Tumor Cells
Photochemistry and Photobiology, Volume 87, Issue 5, pages 1138–1145, September/October 2011, DOI: 10.1111/j.1751-1097.2011.00950.x
Yoshiko Ohgari, Yoshinobu Miyata, Taeko Miyagi, Saki Gotoh, Takano Ohta, Takao Kataoka, Kazumichi Furuyama and Shigeru Taketani
"The decrease of mitochondrial utilization of iron by the knockdown of mitoferrin-2 and frataxin also enhanced the ALA effect."
Yoshiko Ohgari, Yoshinobu Miyata, Taeko Miyagi, Saki Gotoh, Takano Ohta, Takao Kataoka, Kazumichi Furuyama and Shigeru Taketani
"The decrease of mitochondrial utilization of iron by the knockdown of mitoferrin-2 and frataxin also enhanced the ALA effect."
Friday, September 2, 2011
PEP-1-Frataxin Significantly Increases Cell Proliferation and Neuroblast Differentiation by Reducing Lipid Peroxidation in the Mouse Dentate Gyrus.
Neurochem Res. 2011 Sep 1,
Kim W, Kim DW, Shin BN, Yoo DY, Nam SM, Kim MJ, Choi JH, Yoon YS, Won MH, Choi SY, Hwang IK.
Department of Anatomy and Cell Biology, College of Veterinary Medicine, and Research Institute for Veterinary Science, Seoul National University, South Korea.
Keywords: Frataxin, cell proliferation, neuroblast differentiation, PEP-1-frataxin fusion protein, decreasing lipid peroxidation, blood-brain barrier, dentate gyrus.
Kim W, Kim DW, Shin BN, Yoo DY, Nam SM, Kim MJ, Choi JH, Yoon YS, Won MH, Choi SY, Hwang IK.
Department of Anatomy and Cell Biology, College of Veterinary Medicine, and Research Institute for Veterinary Science, Seoul National University, South Korea.
Keywords: Frataxin, cell proliferation, neuroblast differentiation, PEP-1-frataxin fusion protein, decreasing lipid peroxidation, blood-brain barrier, dentate gyrus.
Thursday, September 1, 2011
Articulatory Kinematics in the Dysarthria Associated with Friedreich's Ataxia.
Motor Control. 2011 Jul;15(3):376-89.
Folker JE, Murdoch BE, Cahill LM, Rosen KM, Delatycki MB, Corben LA, Vogel AP.
School of Health and Rehabilitation Sciences, The University of Queensland, St Lucia, Qld, Australia.
KEYWORDS: Electromagnetic articulography (EMA), dysarthria, Friedreich's ataxia (FRDA).
Folker JE, Murdoch BE, Cahill LM, Rosen KM, Delatycki MB, Corben LA, Vogel AP.
School of Health and Rehabilitation Sciences, The University of Queensland, St Lucia, Qld, Australia.
KEYWORDS: Electromagnetic articulography (EMA), dysarthria, Friedreich's ataxia (FRDA).
Drug first to demonstrate neurological improvement in patients with Friedreich’s ataxia
Website: USF HEALTH (UNIVERSITY OF SOUTH FLORIDA)
Preliminary trial findings shared with FARA-USF research symposium participants
"For the first time, an investigative drug has significantly improved the neurological function of patients with Friedreich’s ataxia."
“This is the first clinical trial where patients were given a drug and they’ve shown neurological improvement,” Farmer said. “It’s incredibly hopeful… but there’s still a lot of work ahead. We need to show the drug really makes a difference over six months or a year.”
read more....
Preliminary trial findings shared with FARA-USF research symposium participants
"For the first time, an investigative drug has significantly improved the neurological function of patients with Friedreich’s ataxia."
“This is the first clinical trial where patients were given a drug and they’ve shown neurological improvement,” Farmer said. “It’s incredibly hopeful… but there’s still a lot of work ahead. We need to show the drug really makes a difference over six months or a year.”
read more....
Friday, August 26, 2011
Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with Hereditary Ataxia
Journal of Translational Medicine 2011, 9:65 doi:10.1186/1479-5876-9-65
OPEN ACCESS
Wan-Zhang Yang1, Yun Zhang2, Fang Wu1, Min Zhang1, SC Cho3, Chun-Zhen Li1, Shao-Hui Li1, Guo-Jian Shu1, You-Xiang Sheng1, Ning Zhao1, Ying Tang1, Shu Jiang2, Shan Jiang2, Matthew Gandjian4, Thomas E Ichim4* and Xiang Hu2
1 Department of Rehabilitation Medicine, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, China
2 Shenzhen Beike Cell Engineering Research Institution, Shenzhen, China
3 Department of Neurology and Neurosurgery, Stanford University, Stanford, CA, USA
4 Medistem Inc, San Diego, CA, USA
FULL TEXT PDF
OPEN ACCESS
Wan-Zhang Yang1, Yun Zhang2, Fang Wu1, Min Zhang1, SC Cho3, Chun-Zhen Li1, Shao-Hui Li1, Guo-Jian Shu1, You-Xiang Sheng1, Ning Zhao1, Ying Tang1, Shu Jiang2, Shan Jiang2, Matthew Gandjian4, Thomas E Ichim4* and Xiang Hu2
1 Department of Rehabilitation Medicine, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, China
2 Shenzhen Beike Cell Engineering Research Institution, Shenzhen, China
3 Department of Neurology and Neurosurgery, Stanford University, Stanford, CA, USA
4 Medistem Inc, San Diego, CA, USA
FULL TEXT PDF
The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
Journal of Neuroinflammation 2011, 8:91 doi:10.1186/1742-2094-8-91
OPEN ACCESS
Christine R Swanson, Valerie Joers, Viktorya Bondarenko, Kevin Brunner, Heather A Simmons, Toni E Ziegler, Joseph W Kemnitz, Jeffrey A Johnson and Marina E Emborg
Activation of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) has been proposed as a possible neuroprotective strategy to slow down the progression of early Parkinson's disease (PD). Here we report preclinical data on the use of the PPAR-gamma agonist pioglitazone (Actos(R); Takeda Pharmaceuticals Ltd.) in a paradigm resembling early PD in nonhuman primates.
Clinically, pioglitazone has been tested for Alzheimer disease, multiple sclerosis, autism, stroke, amyotrophic lateral sclerosis, and Friedreich’s Ataxia. The results of these small clinical trials suggest that its administration can benefit patients with neurological disorders.
FULL TEXT PDF
OPEN ACCESS
Christine R Swanson, Valerie Joers, Viktorya Bondarenko, Kevin Brunner, Heather A Simmons, Toni E Ziegler, Joseph W Kemnitz, Jeffrey A Johnson and Marina E Emborg
Activation of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) has been proposed as a possible neuroprotective strategy to slow down the progression of early Parkinson's disease (PD). Here we report preclinical data on the use of the PPAR-gamma agonist pioglitazone (Actos(R); Takeda Pharmaceuticals Ltd.) in a paradigm resembling early PD in nonhuman primates.
Clinically, pioglitazone has been tested for Alzheimer disease, multiple sclerosis, autism, stroke, amyotrophic lateral sclerosis, and Friedreich’s Ataxia. The results of these small clinical trials suggest that its administration can benefit patients with neurological disorders.
FULL TEXT PDF
Subscribe to:
Posts (Atom)
